Test Your Knowledge of NMOSD

ECTRIMS, European Committee for Treatment and Research in Multiple Sclerosis.

  1. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96-103. doi:10.1016/jns.2017.11.022
  2. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:1-15. doi:10.3389/fneur.2018.00888
  3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815.
  4. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197-1204. doi:10.1212/WNL.0b013e3182a6cb5c
  1. Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes on neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e104. doi:10.1212/NXI.0000000000000104
  2. Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11:1-13. doi:10.1177/1756286418761697
  1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815.
  2. Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6:1-14. doi:10.1212/NXI.0000000000000580
  3. Wingerchuk DM, Banwell B, Bennet JL, et al. International panel for NMO diagnosis. Neurology. 2015;85:177-189. doi:10.1212/WNL.0000000000001729
  4. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:1-15. doi:10.3389/fneur.2018.00888
  5. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4‐IgG‐negative NMO spectrum disorder patients are MOG‐IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264:2088-2094. doi:10.1007/s00415-017-8596-7
  1. Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6:1-14. doi:10.1212/NXI.0000000000000580
  2. Mealy MA, Mossburg SE, Kim S-H, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019;28:64-68. doi:10.1016/j.msard.2018.12.011
  3. Traub J, Häusser-Kinzel S, Weber MS. Differential effects of MS therapeutics on B cells—implications for their use and failure in AQP4-positive NMOSD patients. Int J Mol Sci. 2020;21:1-30. doi:10.3390/ijms21145021
  1. Paul F, Marignier R, Palace J; on behalf of the NMOSD Delphi Panel. International, evidence-based Delphi consensus on the management of AQP4-IgG positive NMOSD, with a focus on treatment recommendations for eculizumab, inebilizumab and satralizumab. Poster P008 presented at: ECTRIMS 2022 (Amsterdam): October 25-28, 2022.
  2. Weinshenker BG, Wingerchuk DM, Green A, et al. Diagnosis, severity, and recovery of attacks in the N-MOmentum study of inebilizumab neuromyelitis optica spectrum disorder. Poster 358 presented at: The 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 11-13, 2019 in Stockholm, Sweden.
  1. Moore P, Methley A, Pollard C, et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. J Neurol Sci. 2016;360:4-9.
  1. Paul F, Marignier R, Palace J; on behalf of the NMOSD Delphi Panel. International, evidence-based Delphi consensus on the management of AQP4-IgG positive NMOSD, with a focus on treatment recommendations for eculizumab, inebilizumab and satralizumab. Poster P008 presented at: ECTRIMS 2022 (Amsterdam): October 25-28, 2022.
  2. Xu Y, Ren Y, Li X, et al. Persistently gadolinium-enhancing lesion is a predictor of poor prognosis in NMOSD attack: a clinical trial. Neurotherapeutics. 2021;18:868-877.
  3. Solomon JM, Paul F, Chien C. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord. 2021;14:1-18. doi:10.1177/17562864211014389